<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; WIPO</title>
	<atom:link href="http://www.tapanray.in/tag/wipo/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Utility Model: Would It Work In India For Pharma?</title>
		<link>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=utility-model-would-it-work-in-india-for-pharma</link>
		<comments>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/#comments</comments>
		<pubDate>Mon, 08 Jun 2015 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Biogen]]></category>
		<category><![CDATA[dimethyl]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[Discussion]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Forward Pharma A/S]]></category>
		<category><![CDATA[fumarate]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section 3d]]></category>
		<category><![CDATA[Tank]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tecfidera]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[Utility]]></category>
		<category><![CDATA[Utility Model]]></category>
		<category><![CDATA[WIPO]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6704</guid>
		<description><![CDATA[The revised draft of India&#8217;s IPR Policy penned by the Government constituted ‘Think-Tank’ in 2014, suggests enactment of new laws, such as for ‘Utility Models’ and Trade Secrets, to fill some gaps in the country&#8217;s IPR ecosystem . However, media reports &#8230; <a href="http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Big Pharma&#8217; Prowls Falter: Triggers Off Yet Another Critical Debate</title>
		<link>http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-prowls-falter-triggers-off-yet-another-critical-debate</link>
		<comments>http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/#comments</comments>
		<pubDate>Mon, 25 Nov 2013 00:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[council. India]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fostering]]></category>
		<category><![CDATA[French]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[link]]></category>
		<category><![CDATA[negative]]></category>
		<category><![CDATA[off]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pitroda]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Professor]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sam]]></category>
		<category><![CDATA[SME]]></category>
		<category><![CDATA[sparks]]></category>
		<category><![CDATA[stricter]]></category>
		<category><![CDATA[stumbles]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[triggers]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Wharton]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[WIPO]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3101</guid>
		<description><![CDATA[The &#8216;Big Pharma&#8217; prowls faltered yet again exposing the ‘fault line’ to all, when the GSK global head honcho, a pharma icon in his own right, Sir Andrew Witty supported the pharmaceutical policy of India, while in the country earlier &#8230; <a href="http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In the Pharmaceutical Space: The Dragon breathes fire</title>
		<link>http://www.tapanray.in/in-the-pharmaceutical-space-the-dragon-breathes-fire/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-the-pharmaceutical-space-the-dragon-breathes-fire</link>
		<comments>http://www.tapanray.in/in-the-pharmaceutical-space-the-dragon-breathes-fire/#comments</comments>
		<pubDate>Mon, 09 Apr 2012 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[BCG]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[breathes]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Dragon]]></category>
		<category><![CDATA[fire]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[globalization]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[PCT]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Space]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[WIPO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=110</guid>
		<description><![CDATA[Currently both China and India, the two most populous nations of the world are also the front runners of the global economy in terms of the pace of GDP growth. The economies of the two countries are greatly influenced by &#8230; <a href="http://www.tapanray.in/in-the-pharmaceutical-space-the-dragon-breathes-fire/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-the-pharmaceutical-space-the-dragon-breathes-fire/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Innovation, IPR and Altruism in Public Health</title>
		<link>http://www.tapanray.in/innovation-ipr-and-altruism-in-public-health/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=innovation-ipr-and-altruism-in-public-health</link>
		<comments>http://www.tapanray.in/innovation-ipr-and-altruism-in-public-health/#comments</comments>
		<pubDate>Thu, 26 Nov 2009 01:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Altruism]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[WIPO]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=715</guid>
		<description><![CDATA[The ongoing debate on innovation, Intellectual Property Rights (IPR) and public health is gaining momentum.Even in India, the experts and various stakeholders of the pharmaceutical industry got involved in an interactive discussion with the Director General of the World Intellectual &#8230; <a href="http://www.tapanray.in/innovation-ipr-and-altruism-in-public-health/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/innovation-ipr-and-altruism-in-public-health/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Recent efforts to improve the functioning of the WIPO-administered Patent Cooperation Treaty (PCT) is a welcome step for the interest of India.</title>
		<link>http://www.tapanray.in/recent-efforts-to-improve-the-functioning-of-the-wipo-administered-patent-cooperation-treaty-pct-is-a-welcome-step-for-the-interest-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=recent-efforts-to-improve-the-functioning-of-the-wipo-administered-patent-cooperation-treaty-pct-is-a-welcome-step-for-the-interest-of-india</link>
		<comments>http://www.tapanray.in/recent-efforts-to-improve-the-functioning-of-the-wipo-administered-patent-cooperation-treaty-pct-is-a-welcome-step-for-the-interest-of-india/#comments</comments>
		<pubDate>Mon, 26 Oct 2009 01:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[administered]]></category>
		<category><![CDATA[Cooperation]]></category>
		<category><![CDATA[efforts]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[functioning]]></category>
		<category><![CDATA[improve]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[PCT]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Recent]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Treaty]]></category>
		<category><![CDATA[welcome]]></category>
		<category><![CDATA[WIPO]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=745</guid>
		<description><![CDATA[As the third largest user among developing countries of the PCT system, India has a particular interest in ensuring that the PCT system supports its innovators and exporters in the most efficient manner possible. What does PCT system do? The &#8230; <a href="http://www.tapanray.in/recent-efforts-to-improve-the-functioning-of-the-wipo-administered-patent-cooperation-treaty-pct-is-a-welcome-step-for-the-interest-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/recent-efforts-to-improve-the-functioning-of-the-wipo-administered-patent-cooperation-treaty-pct-is-a-welcome-step-for-the-interest-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
